1naresh
Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)
1naresh
Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)


Table 1: 
Six-month (or first follow-up) outcome by allocation and by group
RupturedUnrupturedAll
Cerecyte (n = 109) (No.) (%)Bare Platinum (n = 112) (No.) (%)PCerecyte (n = 119) (No.) (%)Bare Platinum (n = 123) (No.) (%)PCerecyte (n = 228) (No.) (%)Bare Platinum (n = 235) (No.) (%)P
mRS 064 (58.7)62 (55.4)a93 (78.2)a100 (81.3)a157 (68.9)162 (68.9)
mRS 131 (28.4)b43 (38.4)b17 (14.3)16 (13.0)48 (21.1)59 (25.1)
mRS 28 (7.3)5 (4.5)4 (3.4)7 (5.7)12 (5.3)12 (5.1)
mRS 32 (1.8)0 (0.0)3 (2.5)0 (0.0)5 (2.2)0 (0.0)
mRS 41 (0.9)1 (0.9)1 (0.8)0 (0.0)2 (0.9)1 (0.4)
mRS 50 (0.0)0 (0.0)0 (0.0)0 (0.0)0 (0.0)0 (0.0)
Deathc3 (2.8)1 (0.9)1 (0.8)0 (0.0)4 (1.8)1 (0.4)
mRS ≥3, including deathd6 (5.5)2 (1.8).0705 (4.2)0 (0.0)0.01111 (4.8)2 (0.9).0049
  • 


    ↵a Four patients with mRS 0 had first follow-up at >12 months (14, 20, 21, and 22 months).
    

  • 


    ↵b Two patients with mRS 1 had first follow-up at >12 months (13 and 14 months).
    

  • 


    ↵c Causes of death: in-hospital: 1 delayed cerebral ischemia due to vasospasm, 1 postprocedural acute rebleed. Postdischarge: 1 pulmonary embolism, 1 coronary disease, and 1 respiratory.
    

  • 


    ↵d P values are for 1-sided Blackwelder tests.